

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/990,405
Filing Date	11/21/2001
First Named Inventor	Alan L. Mueller
Group Art Unit	1614
Examiner Name	William R. A. Jarvis
Attorney Docket Number	072827-1905



Sheet 4 of 3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
CTD	A1	3,258,488		Judd et al.	06-28-1966	RECEIVED SEP 16 2003 TECH CENTER 1600/2900
	A2	3,407,258		Harms	10-22-1968	
	A3	3,449,427		Kaiser et al.	06-10-1969	
	A4	4,003,932		Gootjes	01-18-1977	
	A5	4,018,895		Molloy et al.	04-19-1977	
	A6	4,313,896		Molloy et al.	02-02-1982	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CTD	A7	EP	0 000 322 A		Astra Lakemedel Aktiebolag	01-10-1979		
	A8	FR	2 077 916 A		Dainippon Pharmaceutical Co.			
	A9	WO	96/40097 A		NPS Pharmaceuticals, Inc.	12-19-1996		
	A10	WO	97/46511 A		NPS Pharmaceuticals, Inc.	12-11-1997		
	A11	WO	95/21612 A		NPS Pharmaceuticals, Inc.	08-17-1995		
	A12	WO	98/56752 A		NPS Pharmaceuticals, Inc.	12-17-1998		
	A13	GB	1 363 986 A		Gist-Brocades N.V.	08-21-1974		
	A14	GB	1 129 029 A		Boehringer & Soehne GMBH	10-02-1968		
	A15	GB	1 129 210 A		Boehringer & Soehne GMBH	10-02-1968		
	A16	WO	95/15959 A		Schering Corporation	06-15-1995		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
CTD		Andrews et al., "A Pharmacophore hypothesis for antidepressant activity." Quant. Struct. Act. Relat., 6:97-103, 1987.	

Examiner Signature

Date Considered

11/6/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

**BEST AVAILABLE COPY**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/990,405
		Filing Date	11/21/2001
		First Named Inventor	Alan L. Mueller
		Group Art Unit	1614
		Examiner Name	William R. A. Jarvi
(use as many sheets as necessary)		Attorney Docket Number	072827-1905
Sheet	2	of	3



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
CTO	A17	Buck and Amara, "Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants." Molecular Pharmacology, 48:1030-1037, 1995.	
	A18	Carmalm et al., "Antidepressant agents." Acta Pharm. Suec., 12 : 173-182, 1975.	
	A19	Chemical Abstracts Service, Davis, "Antidepressant dibenzo[a,d]cycloheptene derivatives." Database Accession No. 76:1123871 XP002248271.	
	A20	Marcusson et al., "Inhibition of [ <sup>3</sup> H]paroxetine binding by various serotonin uptake inhibitors: structure-activity relationships." European Journal of Pharmacology, 215:191-198, 1992.	
	A21	Maryanoff et al., "Structure-activity studies on antidepressant 2,2-Diarylethylamines." J.Med.Chem., 27:1067-1071, 1984.	
	A22	Melloni et al., "Potential antidepressant agents. $\alpha$ -Aryloxy-benzyl derivatives of ethanolamine and morpholine." European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, 19:235-242, 1984.	
	A23	Merck Index, "Tofenacin" and "Fluoxetine." Whitehouse Station, NJ, p. 1621 and p. 709, 1996.	
	A24	Nowak et al., "Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors." European Journal of Pharmacology, 342: 367-370, 1998."	
	A25	Paul et al., "Adaptation of the N-methyl-D-Aspartate receptor complex following chronic antidepressant treatments." Journal of Pharmacology and Experimental Therapeutics." 269: 95-102, 1994.	
	A26	Van der Zee and Hespe, "A Comparison of the inhibitory effects of aromatic substituted benzhydryl ethers on the uptake of catecholamines and serotonin into synaptosomal preparations of the rat brain." Neuropharmacology, 17:483-490, 1978.	
	A27	Van der Zee and Hespe, "Influence of orphenadrine HCl and its N-Demethylated derivatives on the <i>In Vitro</i> uptake of Noradrenaline and 5-Hydroxytryptamine by rat brain slices." Neuropharmacology, 12:843-851, 1974.	
	CTO	A28	Wilkinson et al., "Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow." Journal of Pharmacology and Experimental Therapeutics, 271(3): 1314-1319, 1994.

Examiner Signature		Date Considered	11/6/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

**BEST AVAILABLE COPY**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/990,405
		Filing Date	11/21/2001
		First Named Inventor	Alan L. Mueller
		Group Art Unit	1614
		Examiner Name	William R. A. Jarvis
Sheet	3	of	3
		Attorney Docket Number	072827-1905



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume, issue, publisher, city and/or country where published.	T <sup>6</sup>
CTO	A29	European Search Report for European Application No. EP 99 93 3987.	

RECEIVED  
SEP 16 2003  
TECH CENTER 1600/2900

Examiner Signature		Date Considered	11/6/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

**BEST AVAILABLE COPY**